240 Leigh Farm Road, Suite 245 | VIA EDGAR |
June 26, 2017
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4546
Washington, D.C. 20549
Attn: Ms. Suzanne Hayes
Ms. Christine Westbrook
Ms. Bonnie Baynes
Ms. Angela Connell
Re: Dova Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-218479
Acceleration Request
Requested Date: | Wednesday, June 28, 2017 |
Requested Time: | 4:00 P.M. Eastern Daylight Time |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-218479) (the “Registration Statement”) to become effective on June 28, 2017, at 4:00 p.m., Eastern Daylight Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Darren K. DeStefano of Cooley LLP, counsel to the Registrant, at (703) 456-8034, or Mark Ballantyne of Cooley LLP at (703) 456-8084.
| Very truly yours, | |
|
| |
| Dova Pharmaceuticals, Inc. | |
|
| |
|
| |
| By: | /s/ Alex Sapir |
|
| Alex Sapir |
|
| President and Chief Executive Officer |
cc: | Douglas Blankenship, Dova Pharmaceuticals, Inc. |
| Divakar Gupta, Cooley LLP |
| Darren K. DeStefano, Cooley LLP |
| Mark Ballantyne, Cooley LLP |
| Deanna Kirkpatrick, Davis Polk & Wardwell LLP |